Abliva AB
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic … Read more
Abliva AB (ABLI) - Total Assets
Latest total assets as of December 2024: Skr73.55 Million SEK
Based on the latest financial reports, Abliva AB (ABLI) holds total assets worth Skr73.55 Million SEK as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abliva AB - Total Assets Trend (2007–2024)
This chart illustrates how Abliva AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abliva AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Abliva AB's total assets of Skr73.55 Million consist of 66.6% current assets and 33.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 44.4% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr11.11 Million | 15.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Abliva AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abliva AB's current assets represent 66.6% of total assets in 2024, an increase from 41.8% in 2007.
- Cash Position: Cash and equivalents constituted 44.4% of total assets in 2024, up from 10.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 15.1% of total assets.
Abliva AB Competitors by Total Assets
Key competitors of Abliva AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Abliva AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Abliva AB generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Abliva AB is currently not profitable relative to its asset base.
Abliva AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.13 | 3.80 | 3.84 |
| Quick Ratio | 4.13 | 3.80 | 3.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr37.08 Million | Skr 45.80 Million | Skr 23.21 Million |
Abliva AB - Advanced Valuation Insights
This section examines the relationship between Abliva AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.58 |
| Latest Market Cap to Assets Ratio | 0.63 |
| Asset Growth Rate (YoY) | -15.9% |
| Total Assets | Skr73.55 Million |
| Market Capitalization | $46.60 Million USD |
Valuation Analysis
Below Book Valuation: The market values Abliva AB's assets below their book value (0.63 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Abliva AB's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Abliva AB (2007–2024)
The table below shows the annual total assets of Abliva AB from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr73.55 Million | -15.94% |
| 2023-12-31 | Skr87.50 Million | -52.40% |
| 2022-12-31 | Skr183.83 Million | +212.01% |
| 2021-12-31 | Skr58.92 Million | -60.89% |
| 2020-12-31 | Skr150.66 Million | +1.46% |
| 2019-12-31 | Skr148.49 Million | +28.78% |
| 2018-12-31 | Skr115.31 Million | -3.99% |
| 2017-12-31 | Skr120.11 Million | -33.54% |
| 2016-12-31 | Skr180.72 Million | +3.31% |
| 2015-12-31 | Skr174.93 Million | +33.26% |
| 2014-12-31 | Skr131.27 Million | +47.20% |
| 2013-12-31 | Skr89.18 Million | +24.71% |
| 2012-12-31 | Skr71.51 Million | +111.41% |
| 2011-12-31 | Skr33.82 Million | -19.77% |
| 2010-12-31 | Skr42.16 Million | +273.43% |
| 2009-12-31 | Skr11.29 Million | -8.49% |
| 2008-12-31 | Skr12.34 Million | +306.63% |
| 2007-12-31 | Skr3.03 Million | -- |